| Q93109968 | 18F-Fluoromethylcholine-positron emission tomography/computed tomography for diagnosing bone and lymph node metastases in patients with intermediate- or high-risk prostate cancer |
| Q92503500 | A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [18F]fluoride: Will [18F]AlF Replace 68Ga for Metal Chelate Labeling? |
| Q88413715 | A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies |
| Q52618074 | A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. |
| Q61454330 | A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion |
| Q49713199 | Advances in prostate-specific membrane antigen PET of prostate cancer |
| Q90719691 | Androgen deprivation therapy in prostate cancer: new findings and questions for the future |
| Q57071079 | Clinical perspectives of PSMA PET/MRI for prostate cancer |
| Q92276001 | Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis |
| Q89638529 | Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity |
| Q49318705 | Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. |
| Q92306387 | Enhancing CAR T-cell therapy through cellular imaging and radiotherapy |
| Q91624218 | Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis |
| Q64068001 | How clinical imaging can assess cancer biology |
| Q92343797 | Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents |
| Q64054352 | Intra-individual comparison of Ga-PSMA-11 and F-DCFPyL normal-organ biodistribution |
| Q58102530 | Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer |
| Q92182846 | Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer |
| Q61449123 | Radiation dosimetry of [Ga]PSMA-11 in low-risk prostate cancer patients |
| Q58577276 | Radioguided surgery with β radiation: a novel application with Ga |
| Q88981178 | Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG |
| Q50034009 | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
| Q90520958 | Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors |
| Q58764832 | Subcellular Targeting of Theranostic Radionuclides |
| Q61810041 | Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer |
| Q52590598 | Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007. |
| Q91050162 | Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer |
| Q92328611 | Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer |
| Q90196812 | Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines |
| Q92235800 | qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT |